During the past decade, Kentuckiana Pulmonary Associates conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 23 clinical trials were completed, i.e. on average, 143.8% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 12 clinical trials were completed. i.e. 600% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kentuckiana Pulmonary Associates" #1 sponsor was "Actelion" with 16 trials, followed by "United Therapeutics" with 11 trials sponsored, "Gilead Sciences" with 4 trials sponsored, "Aires Pharmaceuticals, Inc." with 2 trials sponsored and "Eiger BioPharmaceuticals" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kentuckiana Pulmonary Associates" #1 collaborator was "Lung Biotechnology PBC" with 2 trials as a collaborator, "Canadian Heart Research Centre" with 1 trials as a collaborator and "University of Washington, the Collaborative Health Studies Coordinating Center" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Kentuckiana Pulmonary Associates" are "Pulmonary Arterial Hypertension" (27 trials), "Pulmonary Hypertension" (10 trials), "Idiopathic Pulmonary Fibrosis" (4 trials), "Chronic Obstructive Pulmonary Disease" (2 trials) and "Bronchiectasis" (1 trials). Many other conditions were trialed in "Kentuckiana Pulmonary Associates" in a lesser frequency.

Most popular intervention types in "Kentuckiana Pulmonary Associates" are "Drug" (38 trials), "Other" (4 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Macitentan" (6 trials), "Selexipag" (3 trials), "placebo" (3 trials) and "Ambrisentan" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kentuckiana Pulmonary Associates" are 42 trials for "All" genders.

Currently, there are NaN active trials in "Kentuckiana Pulmonary Associates". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Kentuckiana Pulmonary Associates, undefined suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Kentuckiana Pulmonary Associates, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".